Q3 FY2026
Filed Nov 12, 2026VolitionRx reports Q3 2026 revenue of approximately $1.6 million, up 157%, and a narrower operating loss of $3.3 million, while cutting costs and prepaying its $7.5 million convertible note
Revenue rose and the operating loss narrowed, and the company prepaid its convertible note in cash. The release shows a net loss of $3.8 million, cash of approximately $2.4 million at September 30, 2026, and no guidance. The revenue increase is attributed by the company to higher recognition of deferred revenue.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenue, Q3 2026other | approximately $1.6 million | – | up 157% |
| Operating expenses, Q3 2026other | Not printed as a dollar amount | – | 14% lower |
| Operating loss, Q3 2026other | $3.3M | – | 35% improvement |
| Net loss, Q3 2026other | $3.8M | – | – |
| Non-cash charges related to convertible notes included in Q3 2026 net lossother | $400K | – | – |
| Cash and cash equivalents, as of September 30, 2026other | approximately $2.4 million | – | – |
| Net proceeds from at-the-market facility, Q3 2026other | approximately $5.2 million | – | – |
Capital returns
- No share repurchases or dividends are reported in the release.
- Receipts in the third quarter included approximately $5.2 million in net proceeds from the at-the-market facility.
- The chief executive has voluntarily agreed to a further reduction in base salary, effective November 1, 2026, to 50% of its original level until a substantial licensing agreement is executed.
- The chairman and the entire board have agreed to reduce their cash fees by at least 50%.
What drove it
- The company states that the revenue increase reflects an increase in recognition of deferred revenue.
- The company states that operating expenses were 14% lower than in Q3 2025, reflecting savings from its ongoing cost-reduction program, including a 28% reduction in headcount compared to the same point last year.
- The release states that the operating loss narrowed to $3.3 million from $5.1 million in Q3 2025, a 35% improvement, without attributing a specific cause.
- The company states it cut costs and significantly reduced convertible note debt.
- In September the company participated in the launch of DETECSEPS, a French government-funded program of €6.3 million evaluating its automated Nu.Q NETs assay for early detection of sepsis in hospital emergency departments.
- Critical Care Medicine published data in August showing Nu.Q NETs H3.1 to be an independent predictor of 28-day mortality and need for renal replacement therapy in sepsis.
- In October the company signed a Letter of Intent with Missionpharma, a global distributor of healthcare products serving over 100 million patients annually, with initial efforts focused on triaging and prognostication for neonatal sepsis.
Concerns
- Revenue of approximately $1.6 million is set beside a net loss of $3.8 million for the same quarter. The release does not print a gross margin, cost of revenue or cash burn figure.
- Cash and cash equivalents were approximately $2.4 million at September 30, 2026. The release names the need for additional financing as a risk, and the quarter included $5.2 million of net proceeds from the at-the-market facility.
- The Missionpharma agreement is a Letter of Intent. The safe harbor statement lists a definitive agreement with Missionpharma as a forward-looking item.
- The company's commercialization plan relies on licensing deals that are described as under active discussion. The release gives no signed licensing agreement and no timing for one.
- The $36 billion figure for combined annualized addressable markets is described as Volition's internal estimate based on its TAM model.
What to watch
- Submission of the French reimbursement dossier for Nu.Q Lung Cancer, which the CEO said the company expects to submit this quarter.
- Publication of the feline lymphoma clinical manuscript, which the CEO said is anticipated this quarter. A peer-reviewed publication showing clinical utility is described as a necessary condition to unlock a $5 million milestone payment.
- Progress toward a definitive agreement with Missionpharma and the outcome of active licensing discussions for Capture-Seq in MCED and MRD.
- Revenue recognition from deferred revenue in future quarters, given that the company attributes the Q3 increase to that factor.
- Cash position and additional financing use, given the cash balance and the at-the-market facility proceeds in the quarter.
- Conference call on November 13, 2026 at 8:30 a.m. U.S. Eastern Time.
Balance sheet and cash flow
- Cash and cash equivalents totaled approximately $2.4 million as of September 30, 2026, compared with $1.1 million as of December 31, 2025. The December 31, 2025 date is not the same period as the prior-year quarter, so it is not entered as a prior-year figure.
- During the third quarter, the company prepaid in cash the outstanding balance of its $7.5 million convertible note.
- Net loss of $3.8 million includes non-cash charges of $0.4 million related to convertible notes.
- Operating cash flow, free cash flow, total assets, total equity and total debt outstanding after the prepayment are not printed in the release.
Analysis
VolitionRx reported Q3 2026 revenue of approximately $1.6 million, up 157% from $0.6 million in Q3 2025. The company attributes the increase to a higher recognition of deferred revenue, so the release does not present it as product or test sales growth. The release gives no segment, geographic or product-line revenue split, no gross margin and no cost of revenue. Revenue is therefore a single printed figure whose composition the company explains only in general terms.
Operating expenses were 14% lower than in Q3 2025, and the company links this to its cost-reduction program, including a 28% reduction in headcount against the same point last year. The release does not print operating expenses in dollars, so the size of the cost base cannot be read directly. The operating loss narrowed to $3.3 million from $5.1 million, a 35% improvement. The company's own explanation for the narrowing is the cost program and the higher revenue recognition, both described in the release.
Net loss was $3.8 million, compared with $5.4 million in the prior-year quarter. The release states that the net loss includes non-cash charges of $0.4 million related to convertible notes. No year-over-year change is printed for the net loss. The release gives no prior-quarter comparison, so the sequential trend cannot be read from it.
On the balance sheet, cash and cash equivalents were approximately $2.4 million at September 30, 2026, against $1.1 million at December 31, 2025. The quarter included approximately $5.2 million in net proceeds from the at-the-market facility, and the company prepaid in cash the outstanding balance of its $7.5 million convertible note. The release does not print total debt after the prepayment, operating or free cash flow, or total assets and equity. Capital allocation in the period therefore centers on equity raised through the at-the-market facility and debt reduction, with cost cuts and executive and board fee reductions also announced.
The release contains no financial guidance. Its forward-looking content concerns milestones: a French reimbursement submission for Nu.Q Lung Cancer and publication of the feline lymphoma study, both expected this quarter, and a licensing push for Capture-Seq, supported by a Letter of Intent with Missionpharma signed in October. The reader should weigh the revenue and loss improvements against the cash balance, the reliance on the at-the-market facility and the fact that the commercial agreements named remain in negotiation or letter-of-intent form.
Management, verbatim
At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.
Cameron Reynolds, President and Group Chief Executive Officer
We currently expect to submit this quarter. Achieving reimbursement would be an important step on the path to routine clinical use in France before rolling out to additional geographies.
Cameron Reynolds, President and Group Chief Executive Officer
I am personally leading our most advanced partner negotiations and, to underline my commitment to closing them, have voluntarily agreed to a further reduction in my base salary, effective November 1, 2026, such that my annual base salary is now 50% of its original level, until execution of a substantial licensing agreement.
Cameron Reynolds, President and Group Chief Executive Officer
Not in the filing
stated, not guessed- Operating expenses in dollars for Q3 2026 and Q3 2025
- Prior-year net loss change (percentage or dollar) as printed for net loss
- Prior-quarter (Q2 2026) revenue, operating loss, net loss and cash figures
- Gross margin, cost of revenue and gross profit
- Earnings per share, GAAP or non-GAAP
- Operating cash flow, investing cash flow and free cash flow
- Total assets, total liabilities and total equity
- Total debt outstanding after the convertible note prepayment
- Segment or geographic revenue breakdown
- Financial guidance or outlook for future periods
- Basis (GAAP or non-GAAP) of the operating loss and net loss as presented
- Shares outstanding and share issuance details for the at-the-market facility
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.